⌕
GSK · GSK · NYSE
Tenet 51 · Mixed
Compare
$50.41−0.08%At closeTenet 51 · Mixed
$50.41−0.04 (−0.08%)
At close: Nov 16, 2026, 4:00 PM ET· NYSE · USD
$50.410.00 (0.00%)
After hours: Nov 16, 2026, 4:47 PM ET

GSK Income Statement

Is this a real, growing, cash-generative business, or a story propped up by accounting?

Sources Company filings FilingsHow we compute thisNot investment advice
Business engineSteady: revenue compounds ~7.1%/yr (FY21→FY25), net margin 19.3%.
The four lines that matter · FY21–FY25
Revenue ($B)▲11.8%
43.9
FY21→FY25CAGR +7.1%/yr
Net income ($B)▲128.9%
8.5
one-off year: see footnoteCAGR +5.3%/yr
Free cash flow ($B)▲97.7%
8.8
FY21→FY25CAGR —
Diluted EPS▲139.7%
1.87
buyback-liftedCAGR +3.7%/yr
What the receipts whisper · what a headline number hides
Share count
−19.9%

5.4bn → 4.3bn diluted shares since FY21. Part of EPS growth is the shrinking denominator. Watch net income too.

Capex
$1.8B

−51.5% YoY in FY25 · 4.1% of revenue.

Returns vs FCF
66%

$5.8B returned vs $8.8B of FCF in FY25. Buybacks + dividends covered by cash flow.

What the income statement says · FY21–FY25
Where every revenue dollar goes · FY25 ($B)43.9Revenue−12.1COGS31.8Gross profit−10.1R&D−12.2SG&A10.7Op income−2.2Tax & other8.5Net income

19¢ of every revenue dollar becomes profit. The biggest cost lever is operating expenses.

Margin trend · direction beats level Gross Operating Net
806040200%sector median net margin ~4%FY21FY25

Over this window: gross 66.9% → 72.4%. Net margin 19.3% is more than double the sector median.

The receipt · income statement · FY21–FY25 USD millions except per-share & ratios · hover a line for its definition
USD millions except per-share & ratios
Line itemFY25 †FY25FY24FY23FY22FY21YoYCAGR 21→25
Revenue & profitability
Revenue
43,927.343,927.339,285.938,647.035,414.633,339.6▲11.8%+7.1%
Cost of revenue
12,125.212,125.211,329.010,914.411,538.411,020.0▲7.0%+2.4%
Gross profit
31,802.231,802.227,956.927,732.623,876.222,319.5▲13.8%+9.3%
Research & development
10,118.910,118.98,014.77,930.06,627.96,775.6▲26.3%+10.5%
Selling, general & admin
12,220.612,220.613,791.911,959.310,110.99,544.5▼11.4%+6.4%
Total operating expenses
22,318.022,318.023,714.820,350.617,022.517,000.5▼5.9%+7.0%
Operating incomefeeds ROC rank
10,666.210,666.25,034.78,595.27,769.15,881.9▲111.9%+16.0%
Other income, net
−714.0−714.0−681.1−867.8−972.2−1,023.3——
Pretax income
9,952.19,952.14,353.67,727.46,796.94,858.6▲128.6%+19.6%
Income tax
1,495.31,495.3658.6963.4853.8112.0▲127.0%+91.1%
Net incomePiotroski ROA ✓feeds Buffett Quality owner earnings
8,456.88,456.83,694.96,764.018,865.56,879.6▲128.9%+5.3%
Per share
Diluted EPSbuyback-sensitive
1.871.870.781.5311.991.61▲139.7%+3.7%
Diluted shares (bn)
4.324.324.314.314.315.39▲0.0%−5.4%
Margins
Gross margin63rd pct in Healthcare
72.4%72.4%71.2%71.8%67.4%66.9%▲1.2pp+5.5pp
Operating margin
24.3%24.3%12.8%22.2%21.9%17.6%▲11.5pp+6.6pp
Net margin84th pct in Healthcare
19.3%19.3%9.4%17.5%53.3%20.6%▲9.8pp−1.4pp
† FY25 = fiscal 2025, through 2025-12-31; the trailing year is not available.FY21 effective tax rate was 2% vs a 13% norm for this window, likely a one-time item; see the filing.
FY16 – FY20 · 5 more years
Unlock the full history →
5 more years of statements and CSV export are on Premium.Premium · $119/yr · 7-day trial · cancel anytimeUnlock with Premium →
Annual report filed 2026-03-06 · view filings on SEC EDGAR ↗ · reported currency USD · as-filed figures may be later restated.
Statements normalized in our fundamentals DB · Not investment advice.

What was GSK's revenue last fiscal year?

GSK reported revenue of $43.9B in fiscal 2025, up 11.8% from fiscal 2024.

What was GSK's net income?

GSK reported net income of $8.5B in fiscal 2025, a net margin of 19.3%.

Annual and quarterly statements as filed, normalized into one comparable shape · Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.